Catalogo dei prodotti della ricerca

PERAGINE, NADIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.256
EU - Europa 894
AS - Asia 479
AF - Africa 12
SA - Sud America 10
OC - Oceania 2
Totale 3.653
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.229
SE - Svezia 330
SG - Singapore 267
IT - Italia 246
IN - India 100
CN - Cina 93
DE - Germania 85
FI - Finlandia 78
UA - Ucraina 32
RO - Romania 28
CA - Canada 27
RU - Federazione Russa 24
GB - Regno Unito 15
BG - Bulgaria 13
AR - Argentina 9
BE - Belgio 9
ID - Indonesia 8
IE - Irlanda 7
TG - Togo 7
GR - Grecia 6
NL - Olanda 6
IR - Iran 4
CH - Svizzera 3
FR - Francia 3
RS - Serbia 3
ZA - Sudafrica 3
AU - Australia 2
EG - Egitto 2
KZ - Kazakistan 2
MK - Macedonia 2
AL - Albania 1
AT - Austria 1
BD - Bangladesh 1
EC - Ecuador 1
HR - Croazia 1
IL - Israele 1
LK - Sri Lanka 1
LT - Lituania 1
MY - Malesia 1
SA - Arabia Saudita 1
Totale 3.653
Salva come PNG Salva come JPEG
Città #
Fairfield 327
Singapore 218
Woodbridge 152
Chandler 151
Houston 139
Ashburn 133
Wilmington 125
Seattle 123
Ann Arbor 117
Cambridge 101
Rome 99
Stockholm 88
Santa Clara 80
Princeton 64
Dearborn 56
San Paolo di Civitate 55
Plano 49
Beijing 41
Boston 40
Bremen 36
Helsinki 35
Lawrence 35
Des Moines 27
Millbury 24
San Diego 22
Andover 16
New York 16
Moscow 14
Jacksonville 13
Sofia 13
Toronto 13
Falkenstein 10
Ottawa 10
Norwalk 9
San Mateo 9
Brussels 8
Federal 8
Hefei 8
Jakarta 8
Dublin 7
Lomé 7
Milan 7
Cagliari 6
Nuoro 6
Southend 6
Boardman 5
Falls Church 5
Mannheim 5
Turin 5
Guangzhou 4
Nanjing 4
Tehran 4
Bühl 3
Gossolengo 3
Indiana 3
Kunming 3
Los Angeles 3
Muizenberg 3
Phoenix 3
Shenyang 3
Solbiate Arno 3
Calolziocorte 2
Catania 2
Duncan 2
Kyzylorda 2
Lucknow 2
Mcallen 2
Montréal 2
Naples 2
Perugia 2
Pisa 2
Prato 2
Solna 2
Sydney 2
Xian 2
Auburn Hills 1
Bari 1
Berlin 1
Bern 1
Canyon Country 1
Changchun 1
Changsha 1
Chongqing 1
Clifton 1
Colombo 1
Council Bluffs 1
Danville 1
Delhi 1
Dhaka 1
Fasano 1
Fiuggi 1
Forest City 1
Fort Worth 1
Frankfurt am Main 1
Fremont 1
Friesland 1
Fuzhou 1
Gostivar 1
Guwahati 1
Hebei 1
Totale 2.643
Salva come PNG Salva come JPEG
Nome #
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. 145
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial 105
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes 92
Atypical chronic myeloid leukemia in a patient with aplastic anemia 92
Functional analysis and gene expression profile of umbilical cord blood regulatory T cells 89
Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases 87
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 87
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug nutlin-3: a proposal for clinical application. 87
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression 87
BCR-ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. 83
The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells 81
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. 79
Angiogenic activity in 1(g)V(H) mutated and unmutated chronic lymphocytic leukemia (CLL): Indications for the therapeutic use of VEGF-signaling inhibitors. 78
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells 78
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 78
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 78
Protein Kinase Gene Expression Profiling and In Vitro Functional Experiments Identify Novel Potential Therapeutic Targets in Adult Acute Lymphoblastic Leukemia 77
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib 77
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. 76
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia 75
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia 72
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications 69
null 68
Clinical responses in allografted acute leukaemia patients with resistant disease using a combined chemo-immunotherapeutic treatment strategy 67
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab 67
Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment 67
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors 67
Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission 65
IgV(H) germline and mutated chronic lymphocytic leukemia (CLL) cases exert a diverse responsiveness upon BCR ligation. 64
null 58
null 58
TH2/TH1 shift under Ibrutinib treatment in chronic lymphocytic leukemia 57
The microRNA (miR) profile in B-cell chronic lymphocytic leukemia (CLL) reveals a differential expression of miR-21, miR-155 and miR-150 between leukemic and normal B lymphocytes, and of miR-150, miR-29bc and miR-223 between IgV(H) mutated and unmutated patients 55
Gene expression profile reveals a unique pattern of protein kinases in chronic lymphocytic leukemia (CLL) potential role of the second generation protein kinase inhibitors 55
A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors 55
Distribution of genetic and molecular prognostic markers in young patients with Chronic Lymphocytic Leukemia (CLL) in different phases of the disease. 54
null 54
EVALUATION OF TP53 MUTATIONS WITH THE AMPLICHIP P53 ARRAY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HIGHER SENSITIVITY AND CORRELATION WITH CLINICAL OUTCOME 53
The antileukemic potential of natural killer cells 49
Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients. 49
ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression 48
BCR stimulation induces a differential microRNA (MIR) profiling between B lymphocytes derived from chronic lymphocytic leukemia (CLL) patients and healthy donors. 46
PARP1 and CHE1 impairment identify a subset of chronic lymphocytic leukemia patients with defective IR-induced apoptosis. 43
White blood cell count at diagnosis and immunoglobulin variable region gene (IGHV) mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. 43
Sialylation regulates migration in chronic lymphocytic leukemia 40
Genomic and functional analyses of chronic lymphocytic leukemia (CLL) cells following IgD stimulation. 40
P53 EVALUATION IN 98 CLL PATIENTS BY AMPLICHIP P53 ARRAY REVEALS A HIGH PERCENTAGE OF MUTATIONS AND POLYMORPHISMS 36
COMPLEX KARYOTYPE AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114) 32
null 31
COMPLEX KARYOTYPE IS ASSOCIATED WITH A LESS FAVORABLE OUTCOME AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114). 30
P53 EVALUATION IN CLL BY P53 ARRAY: A SIMPLE, SENSITIVE AND SPECIFIC METHOD THAT UNRAVELS A HIGH PERCENTAGE OF POLYMORPHISMS AND MUTATIONS 29
Characterization of IG VH4-34 expressed by chronic lymphocytic leukemia (CLL) patients identifies a subset with a virtually identical heavy and light chain third complementary determining region (HCDR3 and LCDR3) 29
Characterization of cellular functions in leukemias 28
A good manufacturing practice method to ex vivo expand natural killer cells for clinical use. 28
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. 28
CYTOGENETIC ABNORMALITIES DEL(17P) AND DEL(11Q) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE STUDY ON 156 YOUNG PATIENTS IN DIFFERENT PHASES OF THE DISEASE 27
TP53 GENE SEQUENCING IDENTIFIES A PECULIAR MUTATION PROFILE AND CORRELATION WITH P53 PROTEIN DYSFUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AT DIFFERENT PHASES OF THE DISEASE 27
HIGH PERIPHERAL BLOOD CONCENTRATION OF REGULATORY T CELLS (TREGS) AFTER AN ALLOGENEIC STEM CELL TRANSPLANT PROTECTS FROM ACUTE GRAFT-VERSUS-HOST DISEASE AND CYTOMEGALOVIRUS REACTIVATION 27
null 27
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study 27
Long-term host immune modulation following tisagenlecleucel administration in patients with diffuse large b-cell lymphoma and b-lineage acute lymphoblastic leukemia 24
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients 24
null 22
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab 20
IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies 19
CD45 antigen negativity in T-lineage ALL correlates with PTPRC mutation and sensitivity to a selective JAK inhibitor. 17
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall 14
Utility of Flow Cytometry Ascitic Fluid Analysis for Rapid Diagnosis of B-Cell Peritoneal Lymphomatosis 14
Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. 11
ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia 9
Neoplastic bone marrow invasion:rapid exclusion of hematological disease by flow cytometric routine panels 9
null 8
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response 7
NG2 molecule expression in acute lymphoblastic leukemia B cells: a flow-cytometric marker for the rapid identification of KMT2A gene rearrangements 5
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling 5
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab 5
Totale 3.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.422
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.422
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020495 0 0 0 0 0 116 106 88 77 50 29 29
2020/2021180 13 45 8 12 2 2 4 26 30 21 13 4
2021/2022756 18 43 42 118 79 16 9 70 45 56 121 139
2022/2023666 127 147 42 81 54 87 12 38 51 2 16 9
2023/2024315 25 48 16 21 21 37 5 28 6 32 45 31
2024/2025572 89 218 60 71 62 72 0 0 0 0 0 0
Totale 3.813